TMCnet News
PixarBio to Participate in Event Addressing Connecticut's Opioid EpidemicPixarBio Corporation ("PixarBio" or "the Company"), a biotechnology company developing a morphine replacement, non-opiate, non-addictive post-surgical pain treatment, today announced that its Chief Executive Officer, Mr. Frank M. Reynolds, will be participating in a discussion panel addressing the opioid and heroin epidemic facing the State of Connecticut titled "The Face of Addiction: A Conversation on Connecticut's Opioid Addiction" hosted by the Nantucket Project. "The abuse and addiction to opioids is a serious global health problem that is having devastating effects on communities all around the world, and I am glad to call further attention to this problem in today's event in Connecticut," commented Frank M. Reynolds, CEO of PixarBio, "It is precisely because of the trauma and tragedy of opiate addiction that PixarBio is developing a novel product, NeuroRelease™, that is designed to eradicate the need for post-surgical use of opioid-based prescription pain relievers that are currently in widespread use for the treatment of acute and chronic pain. I am pleased to join an esteemed panel in addressing this very serious problem and to be a part of the solution, to solving this epidemic." The event information is as follows:
About The Nantucket Project
About PixarBio Corporation
Safe Harbor Statement Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of Biotech and medical device industry regulation and health care legislation in the United States and internationally; global trends on cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; PixarBio's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of PixarBio's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. PixarBio Corp undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be obtained through PixarBio's Corp HQ at 200 Boston Ave, Suite 1875 in Medford, MA 02155. PixarBio Corp is a private corporation.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160830005355/en/ |